United Therapeutics Corp. EVP Paul Mahon Sells 6,000 Shares (UTHR)
United Therapeutics Corp. (NASDAQ:UTHR) EVP Paul Mahon sold 6,000 shares of United Therapeutics Corp. stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $110.78, for a total transaction of $664,680.00. Following the completion of the transaction, the executive vice president now directly owns 34,490 shares in the company, valued at approximately $3,820,802. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
United Therapeutics Corp. (NASDAQ:UTHR) traded up 0.37% on Friday, hitting $111.31. The stock had a trading volume of 569,099 shares. United Therapeutics Corp. has a 52-week low of $51.38 and a 52-week high of $116.65. The stock’s 50-day moving average is $95.60 and its 200-day moving average is $80.57. The company has a market cap of $5.591 billion and a P/E ratio of 20.15.
United Therapeutics Corp. (NASDAQ:UTHR) last announced its earnings results on Tuesday, October 29th. The company reported $2.98 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.59 by $1.39. The company had revenue of $302.20 million for the quarter, compared to the consensus estimate of $279.02 million. During the same quarter in the previous year, the company posted $2.82 earnings per share. The company’s revenue for the quarter was up 24.6% on a year-over-year basis.
A number of research firms have recently commented on UTHR. Analysts at Argus raised their price target on shares of United Therapeutics Corp. from $120.00 to $130.00 in a research note to investors on Tuesday. They now have a “buy” rating on the stock. They noted that the move was a valuation call. Separately, analysts at Jefferies Group raised their price target on shares of United Therapeutics Corp. from $76.00 to $91.00 in a research note to investors on Tuesday, December 24th. They now have a “hold” rating on the stock. Finally, analysts at Ladenburg Thalmann upgraded shares of United Therapeutics Corp. from a “neutral” rating to a “buy” rating in a research note to investors on Monday, December 23rd. They now have a $138.00 price target on the stock. Nine analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $88.21.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.